Evaluation of Safety and Tolerability of HIV-1 Inducers in HIV+ Sub-type B Patients on cART with Undetectable Viral Load

The primary objective of this pilot open-label phase I trial is to evaluate the **safety** and **tolerability** of a combination of two HIV-1 inducers in patients with **HIV** sub-type B who are under combination antiretroviral therapy (cART) with an undetectable viral load. Assessing the safety and tolerability of this combination is clinically relevant as it may inform future therapeutic strategies for managing HIV, particularly in maintaining viral suppression and improving patient outcomes.

The clinical trial focuses on **HIV** and involves a study population exclusively composed of male participants. The age range of the participants includes adults and adolescents, as indicated by the age range categories provided. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. The selection criteria for the trial population, as well as any specific lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Additionally, key inclusion or exclusion criteria have not been specified by the sponsor.

The clinical trial is designed as a **phase I** open-label study to evaluate the safety and tolerability of a combination of two HIV-1 inducers in patients with **HIV** subtype B who are under combination antiretroviral therapy (cART) with an undetectable viral load. The trial is set to commence recruitment on December 14, 2022, and is expected to conclude by December 14, 2028. Participants will be involved in the study for the duration of the trial unless early termination criteria are met. Such criteria may include adverse reactions, withdrawal of consent, or non-compliance with study protocols.

The trial will involve a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will undergo regular follow-up visits to monitor safety, tolerability, and any potential side effects of the investigational combination. These visits will also serve to ensure adherence to the study protocol and to collect necessary data for the evaluation of the trial's objectives. The end-of-study visit will mark the conclusion of a participant's involvement, during which final assessments will be conducted to gather comprehensive data on the long-term effects of the treatment.

The trial's methodology does not include randomization or blinding, as it is an open-label study. This design allows for direct observation of the treatment effects without the influence of placebo or control groups. The primary focus is on safety and tolerability, with data collected throughout the trial to inform future research phases. Participants are expected to remain in the study for its entire duration unless specific conditions necessitate early withdrawal. The trial's findings will contribute to the understanding of the investigational treatment's impact on patients with HIV subtype B.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this clinical trial, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial documentation may be incomplete or that such information is not applicable to this particular study.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on December 14, 2022, with an estimated completion date of December 14, 2028. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology for measuring, collecting, and analyzing these efficacy parameters, consistent with the standards of Phase 3 trials. The schedule for assessments and the tools or instruments to be used are not specified in the available information. The trial's focus is on obtaining robust data to support the efficacy claims of the investigational product, adhering to rigorous clinical and scientific standards.